Deep-sequencing analysis of the gene encoding the hepatitis c virus nonstructural 3-4a protease confirms a low prevalence of telaprevir-resistant variants at baseline and the end of the REALIZE study

Journal of Infectious Diseases

Volumn 210, Issue 12, 2014, Pages 1871-1880

  Dierynck, Inge ^a   Thys, Kim ^a   Ghys, Anne ^a   Sullivan, James C ^b   Kieffer, Tara L ^b   Aerssens, Jeroen ^a   Picchio, Gaston ^c   De Meyer, Sandra ^a  

^a JANSSEN RESEARCH FOUNDATION   (Belgium)

^b VERTEX PHARMACEUTICALS   (United States)

^c JANSSEN RESEARCH AND DEVELOPMENT   (United States)

Author keywords

Deep sequencing technique; Genotype 1; Hcv; Mutation; Population sequencing; Resistance; Telaprevir

Indexed keywords

NONSTRUCTURAL PROTEIN 3; NONSTRUCTURAL PROTEIN 4A; PLACEBO; TELAPREVIR; ANTIVIRUS AGENT; CARRIER PROTEIN; NS3 PROTEIN, HEPATITIS C VIRUS; NS4A COFACTOR PEPTIDE, HEPATITIS C VIRUS; OLIGOPEPTIDE; VIRUS PROTEIN;

ANTIVIRAL RESISTANCE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DEEP SEQUENCING ANALYSIS; DOUBLE BLIND PROCEDURE; GENE SEQUENCE; GENETIC VARIABILITY; HEPATITIS C; HEPATITIS C VIRUS GENOTYPE 1; HUMAN; LIMIT OF DETECTION; MUTATIONAL ANALYSIS; NONHUMAN; PHASE 3 CLINICAL TRIAL; POPULATION SEQUENCING; PREVALENCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SENSITIVITY ANALYSIS; SEQUENCE ANALYSIS; TREATMENT FAILURE; TREATMENT OUTCOME; VIRUS GENOME; ENZYMOLOGY; GENETICS; HEPACIVIRUS; HEPATITIS C, CHRONIC; HIGH THROUGHPUT SEQUENCING; ISOLATION AND PURIFICATION; MUTATION RATE;

ANTIVIRAL AGENTS; CARRIER PROTEINS; DRUG RESISTANCE, VIRAL; HEPACIVIRUS; HEPATITIS C, CHRONIC; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; MUTATION RATE; OLIGOPEPTIDES; PREVALENCE; VIRAL NONSTRUCTURAL PROTEINS;

EID: 84921810516     PISSN: 00221899     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/infdis/jiu340     Document Type: Article

References (26)

1. Lin K, Perni RB, Kwong AD, Lin C. VX-950, a novel hepatitis C virus (HCV) NS3-4A protease inhibitor, exhibits potent antiviral activities in HCV replicon cells. Antimicrob Agents Chemother 2006;50:1813-22.
2. European Medicines Agency. Incivo (telaprevir) tablets. Summary of product characteristics, October 2011. http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Product-Information/human/002313/WC500115529.pdf. Accessed 17 July 2013.
3. Incivek (telaprevir) US FDA prescribing information. http://pi.vrtx.com/files/uspi-telaprevir.pdf. Accessed 17 July 2013.
4. Sherman KE, Flamm SL, Afdhal NH, et al. Response-guided telaprevir combination treatment for hepatitis C virus infection [published correction appears in N Engl J Med 2011;365:1551.]. N Engl J Med 2011;365:1014-24.
5. Jacobson IM, McHutchison JG, Dusheiko G, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011;364:2405-16.
6. Zeuzem S, Andreone P, Pol S, et al. Telaprevir for retreatment of HCV infection. N Engl J Med 2011;364:2417-28.
7. Kieffer TL, De Meyer S, Bartels DJ, et al. Hepatitis C viral evolution in genotype 1 treatment-naïve and treatment-experienced patients receiving telaprevir-based therapy in clinical trials. PLoS ONE 2012;7:e34372.
8. Domingo E. Biological significance of viral quasispecies. Viral Hepatitis Rev 1996;2:247-61.
9. De Meyer S, Dierynck I, Ghys A, et al. Characterization of telaprevir treatment outcomes and resistance in patients with prior treatment failure: results from the REALIZE trial. Hepatology 2012;56:2106-15.
10. Sullivan JC, De Meyer S, Bartels DJ, et al. Evolution of treatment-emergent resistant variants in telaprevir phase 3 clinical trials. Clin Infect Dis 2013;57:221-9.
11. Barzon L, Lavezzo E, Militello V, Toppo S, Palù G. Applications of nextgeneration sequencing technologies to diagnostic virology. Int J Mol Sci 2011;12:7861-84.
12. Codoñer FM, Pou C, Thielen A, et al. Added value of deep sequencing relative to population sequencing in heavily pre-treated HIV-1-infected subjects. PLoS One 2011;6:e19461.
13. Zhang E, Bartels DJ, Frantz JD, et al. Development of a sensitive RT-PCR method for amplifying and sequencing near full-length HCV genotype 1 RNA from patient samples. Virol J 2013;10:53.
14. Bennett S. Solexa Ltd. Pharmacogenomics 2004;5:433-8.
15. Nakamura K, Oshima T, Morimoto T, et al. Sequence-specific error profile of Illumina sequencers. Nucleic Acids Res 2011;39:e90.
16. Sarrazin C, Zeuzem S. Resistance to direct antiviral agents in patients with hepatitis C virus infection. Gastroenterology 2010;138:447-62.
17. Li JZ, Paredes R, Ribaudo HJ, et al. Low-frequency HIV-1 drug resistance mutations and risk of NNRTI-based antiretroviral treatment failure: a systematic review and pooled analysis. JAMA 2011;305:1327-35.
18. Kieffer TL, Sarrazin C, Miller JS, et al. Telaprevir and pegylated interferon-alpha-2a inhibit wild-type and resistant genotype 1 hepatitis C virus replication in patients. Hepatology 2007;46:631-9.
19. Fonseca-Coronado S, Escobar-Gutiérrez A, Ruiz-Tovar K, et al. Specific detection of naturally occurring hepatitis C virus mutants with resistance to telaprevir and boceprevir (protease inhibitors) among treatment-naïve infected individuals. J Clin Microbiol 2012;50:281-7.
20. Nasu A, Marusawa H, Ueda Y, et al. Genetic heterogeneity of hepatitis C virus in association with antiviral therapy determined by ultra-deep sequencing. PLoS One 2011;6:e24907.
21. Kircher M, Kelso J. High-throughput DNA sequencing-concepts and limitations. Bioessays 2010;32:524-36.
22. Zeuzem S, Sulkowski MS, Zoulim F, et al. Long-term follow-up of patients with chronic hepatitis C treated with telaprevir in combination with peginterferon alfa-2a and ribavirin: interim analysis of the EX-TEND study. Hepatology 2010;52(suppl 4):436A.
23. Thomas XV, de Bruijne J, Sullivan JC, et al. Evaluation of persistence of resistant variants with ultra-deep pyrosequencing in chronic hepatitis C patients treated with Telaprevir. PLoS One 2012;7:e41191.
24. Barnard RJ, Howe JA, Ogert RA, et al. Analysis of boceprevir resistance associated amino acid variants (RAVs) in two phase 3 boceprevir clinical studies. Virology 2013;444:329-36.
25. Susser S, Vermehren J, Forestier N, et al. Analysis of long-term persistence of resistance mutations within the hepatitis C virus NS3 protease after treatment with telaprevir or boceprevir. J Clin Virol 2011;520:321-7.
26. Sulkowski MS, Gardiner DF, Rodriguez-Torres M, et al. Sustained virologic response with daclatasvir plus sofosbuvir±ribavirin (RBV) in chronic HCV genotype (GT) 1-infected patients who previously failed telaprevir (TVR) or boceprevir (BOC). J Hepatol 2013;58(suppl 1):S570.